Project Grant R21CA292297
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$158K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program aims to validate a novel mouse model of lung squamous cell carcinoma premalignancy and use it to screen and test new lung cancer prevention agents. The $602,315 award to the University of Colorado-Denver will achieve the following over the 5-year project period from April 2025 to March 2030:
Define the human relevance of the in vivo NTCU/smoke mouse model of...
The University of Chicago was awarded a $230,010 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop innovative methods and tools to investigate the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The research strategy will integrate human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel human-relevant lung adenocarcinoma models. The $160,330 award, effective December 1, 2024 through November 30, 2026, aims to:
Introduce oncogenic mutations into primary human lung stem and progenitor cells to generate organoid models for high-throughput drug testing.
Xenograft the mutated stem/progenitor cells into immunodeficient mouse lungs to develop an...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Icahn School of Medicine at Mount Sinai to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancer (SCLC). The project aims to: 1) determine how cell-of-origin and the transcription factor NKX2-1 impact the evolution and maintenance of epigenomic SCLC states, 2) determine the mechanisms for pulmonary to neuronal...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675 to The University of Texas Southwestern Medical Center to conduct research on the role of Jumonji demethylases in small cell lung cancer (SCLC) and their potential as drug targets. The research aims to investigate whether inhibiting these epigenetic enzymes can block SCLC growth and overcome therapeutic resistance, including in chemotherapy-resistant disease models....
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to investigate a novel tumor suppressive pathway in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to elucidate the biological roles of the stress-activated protein kinase (SAPK) axis in...
The National Cancer Institute (NCI) awarded a $703,410 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, awarded on January 16, 2025, supports a comprehensive research program aimed at understanding and disrupting the adenocarcinoma-to-squamous-cell transition, a cellular plasticity mechanism that enables resistance to KRAS inhibitor therapies in non-small cell lung cancer.
The research involves conducting a...
This Project Grant award of $3,787,956 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research by New York University (NYU) School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The key objectives are to:
Understand how the gene SLFN11 informs chemosensitivity in SCLC subtypes.
Study how replication stress response pathways and replication fork modulators regulate...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting research aimed at developing effective therapeutic strategies for lung cancers with SMARCA4 genetic deficiencies. The primary grantee, The Trustees of Columbia University in the City of New York, will receive $557,418 over the award period from March 2025 to February 2030. The research will use genetically engineered mouse models to assess the impact of...